Biosimilars Seek Regulatory Approval in the U.S. & Europe; Plus MTX Underused in the U.S.

MTX was frequently under dosed, given for an inadequate length of time and rarely switched to the subcutaneous form before biologic therapy initiation. The study’s authors note that switching to subcutaneous MTX prevents the need for or significantly extends the time to starting a biologic. Optimizing MTX dosing could lead to better RA control and significant cost savings.

Michele B. Kaufman, PharmD, CGP, RPh, is a freelance medical writer based in New York City and a pharmacist at New York Presbyterian Lower Manhattan Hospital.

References

Pro Pharma Communications International. EMA recommends approval of etanercept biosimilar. GaBI Online. 2015 Nov 27.
Pro Pharma Communications International. Amgen submits biosimilar adalimumab application to FDA. GaBI Online. 2015 Nov 27.
O’Dell JR, Rohr M, Cohen SB, Thorne JC, Mikuls TR. Underuse of methotrexate (MTX) in the treatment of rheumatoid arthritis (RA) in the United States (US): Results of a comprehensive pharmaceutical claims analysis. Arthritis Rheumatol. 2015;67(suppl 10).

Biosimilars Receive Positive News On Nov. 19, 2015, the European Medicines Agency’s (EMA) Committee for Medicinal Products for Human Use (CHMP) recommended granting marketing authorization for SB4, an etanercept biosimilar product that will be called Benepali.1 If approved, Benepali can be used to treat rheumatoid arthritis (RA), psoriatic arthritis (PsA), axial spondyloarthritis and plaque psoriasis….

The availability of biosimilars for the treatment of patients with rheumatic diseases exploded in 2023. Here’s where we stand and what to expect going forward.

After years of speculation about potential cost savings and debates on safety, biosimilars are about to step onto the stage of rheumatic disease treatment. On Feb. 9, the Arthritis Advisory Committee of the U.S. Food and Drug Administration (FDA) met in Washington, D.C., and recommended the approval of CT-P13, a proposed biosimilar to infliximab (Remicade),…

Rheumatology Drug Updates: Biosimilars Seek Regulatory Approval in the U.S., Europe; Methotrexate Underused

Marching to the Biosimilar Beat: Questions on Rollout Remain

Biosimilars Debate Heats up over Cost Savings, Safety Concerns

The Biosimilars Debate Heats Up: Potential cost savings weighed against patient health & safety

Related Articles